Pharmacyte Biotech Inc. (PMCB) 0.1400 $PMCB
PharmaCyte Biotech's Novel Approach to Brain Cancer
PR Newswire - Thu Apr 09, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech
PR Newswire - Wed Apr 01, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
PharmaCyte Biotech: Trials Set To Start In Q3, I'm Still Skeptical
Jack Banser - at Seeking Alpha - Mon Mar 30, 1:55PM CDT
PharmaCyte Biotech on Track to Commence Clinical Trials
GlobeNewswire - Fri Mar 27, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials.
Goldman Small Cap Research Issues Research Report on PharmaCyte Biotech, Inc.
PR Newswire - Thu Mar 26, 7:40AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a research report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. The report carries a rating and a price target. To view the sponsored research report, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTSMCB).
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
Marketwired - Wed Mar 18, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the chemotherapy drug ifosfamide. It is this treatment (Cell-in-a-Box/ifosfamide) that was just awarded with the U.S. Food and Drug Administration's (FDA) Orphan Drug designation. Armed with the FDA's Orphan Drug designation, PharmaCyte can now take direct aim at becoming the treatment of choice for advanced pancreatic cancer.
PharmaCyte Biotech Provides Update on Corporate Developments and Progress With Cancer and Diabetes Programs
GlobeNewswire - Mon Mar 16, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
PharmaCyte Biotech Announces Launch of New Corporate Website
GlobeNewswire - Mon Mar 09, 9:48AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its new website is now live and can be viewed at www.PharmaCyteBiotech.com.
Building A 'Risk-Adverse' Pot Stock Portfolio
Matthew Finston - at Seeking Alpha - Mon Mar 09, 12:06AM CDT
Pot Stock Crash Redux: $23.3B Loss?
Matthew Finston - at Seeking Alpha - Sun Mar 08, 12:42AM CST
48 Marijuana Stocks - A Post-Mortem: Part I
Anthony Cataldo - at Seeking Alpha - Tue Mar 03, 1:27AM CST
GWPH: 91.12 (+0.18)
PharmaCyte Biotech Initiates Expanded Follow-up Study in the United States on the Accumulation of Malignant Ascites Fluid
GlobeNewswire - Thu Feb 19, 9:14AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the commencement of an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a-Box capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid.
PharmaCyte Biotech Diabetes Consortium Member Publishes Review Article on Use of Genetic Engineering to Treat Diabetes
GlobeNewswire - Fri Feb 13, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies for the treatment of diabetes. The publication, titled "The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue," which was authored by a member of PharmaCyte Biotech's Diabetes Consortium, Prof. Ann M. Simpson and her colleagues at UTS, appeared in the prestigious Nature publishing group scientific journal Gene Therapy. This review can be located by clicking here.
PharmaCyte Biotech Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Feb 11, 6:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
PharmaCyte Biotech's International Diabetes Consortium Sets Path Forward to Develop Novel Treatment for Diabetes
GlobeNewswire - Tue Feb 10, 8:07AM CST
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its international Diabetes Consortium has met to develop the path forward for the development of a novel treatment for insulin-dependent diabetes and that it has appointed Dr. Eva Maria Brandtner Director of Diabetes Program Development. The meeting brought together all members of the Consortium to plan the necessary preclinical studies that will be required to advance its Cell-in-a-Box live-cell encapsulated product for the treatment of diabetes. These studies will be used as a basis to prepare for future clinical trials in humans with diabetes. Dr. Brandtner will lead the planned work of the Consortium.
PharmaCyte Biotech's Diabetes Treatment: How Would It Work?
Marketwired - Fri Feb 06, 8:01AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) -- How much would a cure for diabetes be worth? It's incalculable, but certainly many billions of dollars. Consider the insulin market alone is over $25 billion annually and projected to reach $40 Billion by 2018. Diabetes is a worldwide epidemic with over 350 million diabetes patients globally and growing.
PharmaCyte Biotech Officially Begins Development of Diabetes Treatment With First Preclinical Study
Marketwired - Wed Feb 04, 8:03AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) officially moved beyond the discussion of a diabetes treatment to planting its flag in the multi-billion dollar diabetes industry with its recent announcement that the company has started the first of its preclinical trials related to developing a diabetes treatment.
How High Will Cannabis Stocks Run This Year?
ACCESSWIRE - Wed Feb 04, 7:51AM CST
CORAL GABLES, FL / ACCESSWIRE / February 4, 2015 / Weed is now legal by popular vote in Washington, Colorado, Oregon, and Alaska's anticipated market is slated for full implementation in the near future. It's no surprise that people want to get in on the "ground floor" of the industry and though not everyone has the locale to open up their own storefront, the public markets have offered opportunity for investment into companies that do. Over recent weeks, may of these stocks have begun to rally and are piquing the interests of new and old pot traders market wide.
PharmaCyte Biotech Initiates First Preclinical Study of Its Encapsulated Cell Product for Novel Treatment of Diabetes
GlobeNewswire - Mon Feb 02, 9:06AM CST
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today reported that the first preclinical evaluation of its proprietary Melligen cell line for the treatment of diabetes has commenced in the Institute of Virology, Department of Pathobiology, at the University of Veterinary Medicine in Vienna, Austria. This study is the first of a number of preclinical studies that will be performed. These studies are designed to test the safety, efficacy and dosing of Melligen cells, a human cell line engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body.
PharmaCyte Biotech's Novel Approach to Brain Cancer
PR Newswire - Thu Apr 09, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech
PR Newswire - Wed Apr 01, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
PharmaCyte Biotech: Trials Set To Start In Q3, I'm Still Skeptical
Jack Banser - at Seeking Alpha - Mon Mar 30, 1:55PM CDT
PharmaCyte Biotech on Track to Commence Clinical Trials
GlobeNewswire - Fri Mar 27, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials. Goldman Small Cap Research Issues Research Report on PharmaCyte Biotech, Inc.
PR Newswire - Thu Mar 26, 7:40AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a research report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. The report carries a rating and a price target. To view the sponsored research report, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS
MCB). PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
Marketwired - Wed Mar 18, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the chemotherapy drug ifosfamide. It is this treatment (Cell-in-a-Box/ifosfamide) that was just awarded with the U.S. Food and Drug Administration's (FDA) Orphan Drug designation. Armed with the FDA's Orphan Drug designation, PharmaCyte can now take direct aim at becoming the treatment of choice for advanced pancreatic cancer.
PharmaCyte Biotech Provides Update on Corporate Developments and Progress With Cancer and Diabetes Programs
GlobeNewswire - Mon Mar 16, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level. PharmaCyte Biotech Announces Launch of New Corporate Website
GlobeNewswire - Mon Mar 09, 9:48AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its new website is now live and can be viewed at www.PharmaCyteBiotech.com. Building A 'Risk-Adverse' Pot Stock Portfolio
Matthew Finston - at Seeking Alpha - Mon Mar 09, 12:06AM CDT
Pot Stock Crash Redux: $23.3B Loss?
Matthew Finston - at Seeking Alpha - Sun Mar 08, 12:42AM CST
48 Marijuana Stocks - A Post-Mortem: Part I
Anthony Cataldo - at Seeking Alpha - Tue Mar 03, 1:27AM CST
GWPH: 91.12 (+0.18)
PharmaCyte Biotech Initiates Expanded Follow-up Study in the United States on the Accumulation of Malignant Ascites Fluid
GlobeNewswire - Thu Feb 19, 9:14AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the commencement of an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a-Box capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid.
PharmaCyte Biotech Diabetes Consortium Member Publishes Review Article on Use of Genetic Engineering to Treat Diabetes
GlobeNewswire - Fri Feb 13, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies for the treatment of diabetes. The publication, titled "The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue," which was authored by a member of PharmaCyte Biotech's Diabetes Consortium, Prof. Ann M. Simpson and her colleagues at UTS, appeared in the prestigious Nature publishing group scientific journal Gene Therapy. This review can be located by clicking here. PharmaCyte Biotech Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Feb 11, 6:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
PharmaCyte Biotech's International Diabetes Consortium Sets Path Forward to Develop Novel Treatment for Diabetes
GlobeNewswire - Tue Feb 10, 8:07AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its international Diabetes Consortium has met to develop the path forward for the development of a novel treatment for insulin-dependent diabetes and that it has appointed Dr. Eva Maria Brandtner Director of Diabetes Program Development. The meeting brought together all members of the Consortium to plan the necessary preclinical studies that will be required to advance its Cell-in-a-Box live-cell encapsulated product for the treatment of diabetes. These studies will be used as a basis to prepare for future clinical trials in humans with diabetes. Dr. Brandtner will lead the planned work of the Consortium. PharmaCyte Biotech's Diabetes Treatment: How Would It Work?
Marketwired - Fri Feb 06, 8:01AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) -- How much would a cure for diabetes be worth? It's incalculable, but certainly many billions of dollars. Consider the insulin market alone is over $25 billion annually and projected to reach $40 Billion by 2018. Diabetes is a worldwide epidemic with over 350 million diabetes patients globally and growing.
PharmaCyte Biotech Officially Begins Development of Diabetes Treatment With First Preclinical Study
Marketwired - Wed Feb 04, 8:03AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) officially moved beyond the discussion of a diabetes treatment to planting its flag in the multi-billion dollar diabetes industry with its recent announcement that the company has started the first of its preclinical trials related to developing a diabetes treatment.
How High Will Cannabis Stocks Run This Year?
ACCESSWIRE - Wed Feb 04, 7:51AM CST
CORAL GABLES, FL / ACCESSWIRE / February 4, 2015 / Weed is now legal by popular vote in Washington, Colorado, Oregon, and Alaska's anticipated market is slated for full implementation in the near future. It's no surprise that people want to get in on the "ground floor" of the industry and though not everyone has the locale to open up their own storefront, the public markets have offered opportunity for investment into companies that do. Over recent weeks, may of these stocks have begun to rally and are piquing the interests of new and old pot traders market wide.
PharmaCyte Biotech Initiates First Preclinical Study of Its Encapsulated Cell Product for Novel Treatment of Diabetes
GlobeNewswire - Mon Feb 02, 9:06AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today reported that the first preclinical evaluation of its proprietary Melligen cell line for the treatment of diabetes has commenced in the Institute of Virology, Department of Pathobiology, at the University of Veterinary Medicine in Vienna, Austria. This study is the first of a number of preclinical studies that will be performed. These studies are designed to test the safety, efficacy and dosing of Melligen cells, a human cell line engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body. 
